Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non‐insulin therapies—A randomised controlled trial
Authors' conclusion
The use of isCGM in individuals living with T2DM on non-insulin therapy showed promise in improving glycaemic control, as evidenced by increased TIR, albeit without a significant reduction in HbA1c or impact on diabetes distress, suggesting this could be potentially beneficial in individuals with T2DM.
Study context
- Population
- Adults with T2D receiving non-insulin therapies; median age 59.5 years, 57.5% male
- Participants
- 40 adults
- Comparison
- isCGM vs blinded CGM
- Primary endpoint
- Fall in haemoglobin A1c (HbA1c) of ≥5.5 mmol/mol
- Follow-up
- 12 weeks
Methodological detailspilot
- Pilot
Primary result
As reported in the abstract
HbA1c reduction ≥5.5 mmol/mol
P = 0.34
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| TIR · 12 weeks | improvement 18 percentage points (CI 2–35) | P = 0.028 |
| HbA1c · 12 weeksNon-significant; lower with Libre 2 | reduction 8 mmol/mol |
Other CGM metrics and diabetes distress (diabetes distress scale (DDS2))
- No significant differences between groups in other CGM metrics or diabetes distress
Original publication
Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non‐insulin therapies—A randomised controlled trial. Diabetes Obes Metab. Published 11 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →